Preeclampsia could be treated with 'blood filtering' therapy, early study hints
livescience - A blood-filtering therapy for preeclampsia is safe for pregnant patients and their babies, according to a new pilot study.
AI Summary: Early clinical work suggests removing a circulating anti‑angiogenic factor can safely extend pregnancies in severe preeclampsia. Researchers used targeted extracorporeal filtration to lower soluble Fms‑like tyrosine kinase‑1 (sFlt‑1) levels, improving maternal and fetal stability long enough to delay delivery and reduce immediate risks, meriting larger controlled trials.
Related Stories
Researchers grow liver tissue in patients' bodies; study now under scrutiny / 2 months
Engineered esophagus tissue offers new hope for children with absent organs / 3 months
Studies neglect women's experiences in childbirth and breastfeeding research / 1 month
New science pushes erectile disorder treatment beyond Viagra / 2 months
FDA approves Rocket Pharma gene therapy for ultra‑rare immune disorder / 3 months
New tests could finally shorten the endometriosis diagnostic saga / 8 hrs
Grail’s Galleri blood test misses UK study goal; investor jitters / 4 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Digital Health, Biotech, Vitamin D, Alzheimer's disease and look for the RSS link.
StackHealth Time Machine